HIF1A and cancer: Herein, we designed a hypoxia-sensitive CRISPR–Cas9/dCas9 system by conjugating the oxygen-sensitive domain of HIF-1α to the effector Cas9/dCas9 protein and analyzed the functional activity of this conjugate system and its potential application in cancer therapy.